Drug Specificity
Drug Specificity - Related Videos
09:39
Assessing Specificity of Anticancer Drugs In Vitro
0 Views •
Cited by 8 •
2016
The goal of this protocol is to assess specificity of anticancer drugs in vitro using mixed cultures containing both tumor and non-tumor cells.
01:20
Magnetic Millirobots for Region-Specific Drug Delivery in the Rat Central Nervous System
0 Views •
2025
Begin with a harvested rat brain submerged in artificial cerebrospinal fluid in a petri dish.Deposit the magnetic millirobot onto the brain cortex.The millirobot, termed MANiAC, consists of magnetically aligned nickel nanorods embedded within a microcapsule composed of the biocompatible hydrogel alginate and loaded with a dye as a model drug.Position an external magnetic field generator beneath the petri dish to generate a uniform rotating magnetic field.The nickel nanorods align and rotate...
01:29
Clinically Relevant Drug Product Specifications: Methods of Establishment
0 Views •
2025
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
0 Views •
Cited by 4 •
2016
Here we describe a protocol using the web-based drug repurposing hypothesis generation tool: "RE:fine Drugs." This protocol can be modified to a user's preferences at the level of the query type (gene, drug or disease) and/or the range of available advanced options.
13:34
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
0 Views •
Cited by 29 •
2016
We present a three-dimensional (3D) lung cancer model based on a biological collagen scaffold to study sensitivity towards non-small-cell-lung-cancer-(NSCLC)-targeted therapies. We demonstrate different read-out techniques to determine the proliferation index, apoptosis and epithelial-mesenchymal transition (EMT) status. Collected data are integrated into an in silico model for prediction of drug sensitivity.
FAQs
A drug’s chemical structure determines how well it fits a molecular target and how strongly it binds there. This binding affinity can favor a receptor, enzyme, transporter, or pathway over alternative sites. Comparing these interactions helps pharmacologists connect molecular recognition with the intended therapeutic effect and identify possible sources of unintended activity.
Specificity can decrease as drug concentration rises because higher exposure may promote interactions with alternative targets that have lower affinity. A medicine may therefore produce a preferred effect at one concentration but broader biological effects at another. This concentration-dependent behavior helps explain why dose selection influences both therapeutic responses and adverse reactions.
Distribution determines which tissues and biological sites a drug reaches, while metabolism changes how much of the original compound remains available and may alter its effects. Consequently, target preference can differ across the body and over time. Considering these factors helps explain why molecular selectivity does not always produce identical effects in every tissue.
Molecular target preference influences the relationship between dose and biological response, because stronger or more selective interactions can shape the desired effect at particular exposure levels. Pharmacologists relate these responses to the therapeutic index, which helps compare beneficial and harmful effects. This analysis supports dosing decisions that seek useful activity while limiting unintended consequences.
During drug design, target preference helps researchers favor compounds that act on disease-related mechanisms rather than broadly affecting unrelated biological systems. In treatment selection, this information can help match a medicine’s molecular actions with the desired therapeutic goal. The intended outcome is improved targeting, while recognizing that concentration, distribution, and metabolism can still broaden effects.
Unexpected adverse reactions may indicate that a drug interacts with alternative molecular targets or biological pathways, especially when exposure changes its target preference. Pharmacologists can interpret these effects alongside dose-response information and the therapeutic index. This approach links observed patient responses to molecular activity and can inform choices among medicines with different target profiles.